|
May 8
|
Acadia Pharmaceuticals (ACAD) Tops Q1 Earnings Estimates
|
|
May 8
|
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
|
|
May 6
|
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
|
|
May 4
|
Insider Sale: CEO Stephen Davis Sells Shares of ACADIA Pharmaceuticals Inc (ACAD)
|
|
Apr 29
|
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
|
|
Apr 28
|
ACADIA Pharmaceuticals (NASDAQ:ACAD) shareholders have endured a 37% loss from investing in the stock five years ago
|
|
Apr 24
|
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
|
|
Apr 22
|
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
|
|
Apr 17
|
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
|
|
Apr 10
|
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 26,574 Shares
|
|
Apr 2
|
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
|
|
Apr 1
|
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 28
|
ACADIA Pharmaceuticals Inc CEO Stephen Davis Sells 17,714 Shares
|
|
Mar 14
|
3 Pharma Stocks to Sell in March Before They Crash & Burn
|
|
Mar 13
|
Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
|
|
Mar 12
|
Acadia Hits 11-Month Low After Outsized Placebo Effect Torpedoes Schizophrenia Study
|
|
Mar 11
|
UPDATE 2-Acadia to stop trials of antipsychotic drug after it fails schizophrenia study
|
|
Mar 11
|
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
|
|
Jan 31
|
Acadia Announces Additions to Executive Team
|
|
Jan 30
|
20 Countries With The Highest Number of Drug Trafficking in the World
|